These observations suggest that Myc-overexpressing/amplified SCLC may respond well to the combination of PARP and PI3K inhibition, but this could not be tested in these experiments because of the limited range of response seen in vitro. This evidence concerns the gene PARP1 and small cell lung carcinoma.